• Lexaria’s HYPER-H21-4 human clinical study was a success, producing favorable results in treating hypertension when comparing the company’s patented DehydraTECH(TM) CBD with a placebo
• According to a Zacks SCR report, the findings support their $15 share valuation of the company
• Zacks expects Lexaria to penetrate global markets for hypertension, nicotine delivery and antiviral products
• The hypertension drug market is expected to grow to over $34 billion through 2030, with North America anticipated to hold 35% of the market share

According to the World Health Organization (“WHO”), approximately 1.13 billion people worldwide suffer from hypertension (high blood pressure), with only one in five being treated or under control. The hypertension drug market size in 2021 was valued at $25,394 million and is expected to grow at a CAGR of 3.4% through 2030, resulting in an estimated value of $34,072 million. The North American market is expected to lead with more than 35% of the world market share (https://ibn.fm/QQ33h). Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently released impressive results from its fourth and most comprehensive hypertension study, HYPER-H21-4. The study, structured as a randomized, double-blind, placebo-controlled cross-over study, dosed 66 male and female volunteers between the ages of 40-70 with stage 1 or 2 hypertension, comparing the company’s patented DehydraTECH(TM) cannabidiol (“CBD”) against a placebo. The study showed patients receiving placebo doses trended toward increases in blood pressure (“BP”) during the period of the study compared to baseline, while the average BP measured by each of mean arterial BP, systolic BP and diastolic BP significantly decreased from baseline when dosed with DehydraTECH-CBD; and those decreases were maintained during the full 5 weeks of dosing  – with no serious adverse events or hepatic changes occurring (https://ibn.fm/38KF3). Lexaria’s DehydraTECH technology is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients, increasing effectiveness and improving the way that active pharmaceutical ingredients (“APIs”) enter the bloodstream. In 2021, animal studies demonstrated that DehydraTECH elevated drug quantities across the blood-brain barrier by as much as 1,700%, which initiated further investigations  and opened the possibilities for improved drug delivery. The benefits of using Lexaria’s patented technology include the following:

• Improves the speed of onset, with effects felt in minutes
• Increases bioavailability by more effectively delivering the drug into the bloodstream
• Increases brain absorption, with testing suggesting up to 10x improvement
• Reduces drug administration costs with a higher ratio of drug delivery

Lexaria announced the enrollment for HYPER-H21-4 in an April 19 press release, and dosing began ahead of schedule, with completion on July 27, with no serious adverse events reported as a result of the dosing. The maximum dose levels in the study were roughly 5 mg/kg/day, which is significantly lower than maximum dose levels practiced for other regulator-approved pharmaceutical CBD applications., The company will use data from the study to support its Investigational New Drug (“IND”) application with the FDA. According to a Zacks Small-Cap Research (“Zacks SCR”) report, the company’s next steps for the hypertension program will be to submit and receive clearance for an IND application, and the application and IND clearance will support the start of the Phase Ib study slated for 2023 (https://ibn.fm/L7LRB). Longer term goals for the program are to find a partner who will advance the work to a registrational study and send it to the FDA for approval. While this is several years away, the data that has been released so far is supportive of further development. Zacks SCR forecasts penetration by Lexaria into global markets for hypertension, nicotine delivery, and antiviral product categories. The Zacks SCR valuation of $15 per share assumes a 2024 regulatory approval and commercialization of DehydraTECH CBD in the United States and developed markets – a valuation maintained throughout the report. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• While economies worldwide are struggling to control spiking inflation rates, REZYFi, a mortgage lender servicing non-traditional as well as other loans, sees unique financial opportunities
• Through the use of proprietary automated machine learning and associated technologies, together with preparations to launch a high-margin cannabis division later this year to serve an industry in need of loan origination options, REZYFi is working to grow its operation
• RZFI is licensed in more than 30 U.S. states and expects to expand its loan origination services to all remaining states in coming months

Economic challenges resulting from governmental efforts to tame inflation could in turn create new opportunities for hard-to-finance sector lenders, especially as mortgage rates eventually fall as recently suggested by CNN Business (https://ibn.fm/EBSYB). The fight against inflation has delivered successes in the United States — what investment bank Goldman Sachs refers to as “remarkable” progress in slowing the US economy and easing the concerning imbalance between supply and demand in the jobs market, though Goldman also warns against going too far in the inflation battle. “Fiscal and monetary policy tightening has so far managed to slow demand growth sharply without accidentally overdoing it and sparking a recession, an impressive achievement,” Goldman Sachs economists stated in a recent note to their clients (https://ibn.fm/7HK1I). Specialized financing company REZYFi is pursuing a growth strategy cognizant of the economic pressures, preparing to launch a high-margin cannabis division later this year while managing staffing levels and applying proprietary technologies for efficiency. The cannabis industry has historically struggled with obtaining loans and other bank services because of the U.S. government’s continued regulation of the leafy green plant as a highly controlled substance. State governments have created legalized avenues for the cannabis market in recent years, but the industry continues to hope for better financing conditions, such as those proposed under the Secure and Fair Enforcement (“SAFE”) Banking Act and the Marijuana Opportunity Reinvestment and Expungement (“MORE”) Act that have cleared the House of Representatives and are awaiting a decision from the Senate. The measures would prevent federal regulators from penalizing banks that serve the cannabis industry or decriminalize cannabis outright (https://ibn.fm/C25wP). For REZYFi, all of this has created a significant window of opportunity, of which the company has taken advantage. As a result, the company is now licensed in more than 30 U.S. states, with expectations to expand its loan origination and services to all remaining states. For more information, visit the company’s website at www.REZYFi.com. NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://ibn.fm/REZY

• Climate change and industrialized pollution emissions continue to raise warnings worldwide that the quality of human life is being compromised
• U.S.-based Correlate Infrastructure Partners is working to establish solutions for its clients by assessing utilities inefficiencies, advising on affordable improvements, and then helping to successfully implement changes through access to highly cost-effective financing opportunities
• The federal government’s recent passage of greenhouse gas reduction financing opportunities through the Inflation Reduction Act (“IRA”) has established the government as a ready partner in companies’ ESG policies
• The IRA has become particularly attractive to public, non-profit, and REIT entities because of changes to subsidy availability
• A low increase in global carbon dioxide emissions associated with energy use this year shows that industries are finding increased motivation to improve their greenhouse gas profiles

Progressive tech hub Seattle, where Amazon and Microsoft are headquartered, made headlines last month for an age-old problem — pollution, when Seattle, helped by wildfires, was briefly classified as the worst city worldwide for air quality and pollution, and was kept among the planet’s top polluters for a while even after it fell out of the top spot (https://ibn.fm/rploW). While wildfires and unusually hot, dry climate conditions were blamed for the spike in poor air quality (https://ibn.fm/LIRap), more than a third of the city’s persistent greenhouse pollutants are attributed to climate-unfriendly energy use by residential, commercial and industrial buildings. Efforts to curb the building pollution, not just in Seattle but across the Washington state, has led Washington’s Building Code Council to require heat pump installation in large and commercial buildings by July in a bid to increasingly electrify utilities and move away from carbon-based fuels (https://ibn.fm/9bgta). Clean energy solutions innovator Correlate Infrastructure Partners (OTCQB: CIPI) is committed to facilitating improvements in greenhouse gas reduction through correlated efforts by its subsidiaries to advise the commercial real estate industry (companies that develop and rent out commercial building properties) on opportunities to change their carbon pollutant output and then help them implement those changes with available financing solutions. The Inflation Reduction Act (“IRA”) recently passed by the Biden administration is credited for opening up financing for a large number of pollution-reducing, climate-positive efforts through energy-related tax credits. Subsidies for energy efficiency retrofits and renewable energy installations are expected to be particularly useful for tax-exempt public and non-profit entities as well as real estate investment trusts (“REITs”) because those entities have thus far been unable to find financial incentive to improve their ESG profiles because they don’t have taxable income for decarbonization tax credits to offset. “We can now take 20-30% off the top of capital projects that we would typically need to pass on. Reducing that up front cost opens up a new playbook,” the vice president of REIT Macerich’s Corporate Responsibility and Sustainability division told smart building tech community Nexus Pro last month (https://ibn.fm/QGc8f). Some climate activists have gone so far as to encourage the president to use “the full powers of the federal government” to require huge cuts to building emissions nationwide (https://ibn.fm/eJahH) but Correlate Infrastructure Partners is optimistic that the trend toward increasing ESG investment by the younger generation (https://ibn.fm/YHSVQ) is helping to motivate companies to  clean their own houses. An Oct. 20 report by Scientific American noted that global carbon dioxide emissions associated with energy use are on track to increase 1 percent this year but added that the 1 percent increase is “significantly less than what many observers projected earlier this year” and a landmark step in creating continued climate change solutions (https://ibn.fm/XjgSP). For more information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• The CCPA limits data flows to brands and marketers, and CPRA amendments are set to take effect January 1, 2023
• CPRA and CCPA provisions include the right to opt-out of data sharing and sale, as well as the right to data deletion
• Consumer data is critical to branding and advertising strategies
• Reklaim provides an ecosystem that equips marketers with fully compliant, consumer-verified data sets while rewarding consumers for sharing information

With the aim of protecting consumers, the California Consumer Privacy Act (“CCPA”) and amendments provided by the California Privacy Rights Act (“CPRA”) are gradually transforming the advertising landscape by limiting data flows to brands and advertisers. Reklaim (TSX.V: MYID) (OTCQB: MYIDF) is firmly positioned to fill the void with a privacy-compliant desktop and mobile identity ecosystem that provides relevant datasets to marketers while rewarding consumers for sharing their data. Data fuels the company’s need to market activities for brands and advertisers. However, options are gradually decreasing due to privacy laws restricting information flow of information to the market. One such law is the CCPA, which took effect on January 1, 2020, and is set to be amended by the CPRA on January 1, 2023 (https://ibn.fm/UbGB0). The CCPA’s initial provisions give consumers the right to know what data is collected, why it is collected, if it is sold and what party bought the information. They also offered the right to delete this data. The CPRA adds two additional provisions: the right to correct inaccurate personal information and the right to limit the use and disclosure of sensitive personal data. The CCPA and subsequent CPRA amendments impose these obligations on businesses, service providers, contractors and third parties. Consequences for non-compliance include penalties of up to $7,500 per intentional violation, $2,500 per unintentional violation and statutory damages of up to $750 per consumer per incident. California is the world’s sixth-largest economy, ahead of Italy and closely behind France (https://ibn.fm/nzX82), making it a highly lucrative jurisdiction for brands and advertisers. In addition to severely limiting marketing activities in the United States, similar laws enacted in other countries threaten to greatly reduce the impact of advertising campaigns worldwide (https://ibn.fm/QLTnl). Reklaim is strongly positioned to support brands with fully consensual, consumer-verified data through an ecosystem that rewards users for sharing their data while providing verified datasets advertisers can access for a fee. Besides being fully compliant, Reklaim’s platform offers more relevant and higher-quality data, because consumers on the platform actively provide and choose to share their information. According to Fortune Business Insights, the global customer data platform market was valued at $1.42 billion in 2022 and is expected to reach $6.94 billion by 2029, expanding at a CAGR of 25.4% over the forecast period (https://ibn.fm/ZCUUC). As demand for consumer data continues to rise amid legislative restrictions, Reklaim provides valuable, transparent and high-quality solutions that benefit both sides of the consumer data market. For more information, visit the company’s website at www.ReklaimYours.com. NOTE TO INVESTORS: The latest news and updates relating to MYIDF are available in the company’s newsroom at https://ibn.fm/MYIDF

• CNS Pharmaceuticals is focused on advancing its clinical development for the Berubicin drug candidate in order to bring meaningful treatment to GBM patients
• GBM, which has a low survival rate, has limited treatment options when it progresses after first-line therapy
• The company is looking to find a solution with Berubicin and is currently evaluating this drug candidate in a potentially pivotal global study
• CNS’s ongoing R&D efforts are boosted by its strong cash position; in its Q2 2022 report, the company announced it had cash of about $9.0 million and working capital of $10.5 million

CNS Pharmaceuticals (NASDAQ: CNSP), an oncology drug development company specializing in developing anti-cancer drugs for the treatment of primary and metastatic brain and central nervous system (“CNS”) cancer, started 2022 on a high, closing an $11.5 million private placement whose net proceeds the company intended to deploy toward funding its clinical trials and preclinical programs as well as other research and development (“R&D”) activities and general corporate purposes. The additional funding not only boosted the company’s R&D efforts but also enhanced its cash position, as reflected in its subsequent financial reports (https://ibn.fm/GK93f). In its report for the three months ended June 30, 2022 (“Q2 2022”), CNS Pharmaceuticals had cash and cash equivalents of about $9.0 million and working capital of $10.5 million (https://ibn.fm/UiG9a). And although the figure represented a drop from about $12.4 million and $13.7 million, respectively, recorded in the period ended March 31, 2022 (“Q1 2022”) (https://ibn.fm/ycZXd), the company spent 46% more on R&D in Q2 2022 than in Q1 2022. (Its R&D expenditure in Q2 2022 was $2.2 million.) CNS Pharmaceuticals expects its cash on hand and proceeds from the placement to fund its operations into Q1 2023. The first half of fiscal 2022 saw the company make a number of clinical and operational advancements in its pursuit of treatment for Glioblastoma Multiforme (“GBM”), according to CNS Pharmaceuticals CEO John Climaco. The company’s focus and priorities, Climaco emphasized, are firmly anchored in the advancement of its clinical development for its drug candidate Berubicin with the aim of bringing meaningful treatment to GBM patients. And as he separately told attendees at the recently held H.C. Wainwright 24th Annual Global Investment Conference, this focus is driven by a significant unmet clinical need, especially given that recurrent GBM does not have “an approved therapy anywhere in the world” (https://ibn.fm/ciFue). For GBM patients, this unmet need causes anguish that often culminates in death. A 2021 study, for instance, notes, “Once tumors progress after first-line therapy, treatment options are limited, and the management of recurrent GBM remains a challenge” (https://ibn.fm/4ZfEE). Another, a 2015 study, underlines that recurrence is, unfortunately, inevitable, with its management unclear and case-dependent (https://ibn.fm/DRKYF). These characteristics have meant that GBM remains one of the most aggressive primary brain tumors, with a grim prognosis. Data from the American Cancer Organization shows that GBM has the least 5-year relative survival rate of the various common adult brain and spinal cord tumors in the list. For example, among 20- to 44-year-old patients, the survival rate stands at 22%. This figure drops to 9% among adults aged between 45 and 54 and 6% among those between 55 and 64. In comparison, anaplastic astrocytoma, the condition with the second lowest survival rate in the list, has higher survival rates of 58%, 29%, and 15%, respectively, across the three age categories (https://ibn.fm/IR0ko). The condition’s aggressiveness is further concretized by the fact that over 10,000 patients succumb to GBM annually in the United States, where 13,000 people are diagnosed with GBM every year the average length of survival for GBM patients is estimated to be only eight months. (https://ibn.fm/hUVew). With the survival rate and mortality statistics for GBM remaining virtually unchanged for decades, according to the National Brain Tumor Society, CNS Pharmaceuticals is working hard to find a solution. The company is relying on Berubicin, a novel anthracycline whose mechanism of action is inhibiting the topoisomerase II enzyme that causes cell replication and is abundantly found in tumor cells. CNS Pharmaceuticals has observed that the drug, which appears, based on limited clinical data, to cross the blood-brain barrier, is selectively absorbed in cancerous cells and tissue in the brain. The Berubicin drug candidate solves a problem that has long dogged cancer research for years. Although anthracyclines have existed for the past six decades, they could not cross the blood-brain barrier. CNS Pharmaceutical’s drug candidate, therefore, is the first anthracycline to appear to cross this critical barrier. The company is currently undertaking a potentially pivotal global study evaluating the efficacy and safety of Berubicin compared with Lomustine administered after first-line therapy for the treatment of recurrent GBM. For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• The upcoming COP27 Conference in Egypt will dictate the world’s latest measures designed to adhere to 2015’s Paris Agreement
• With the world increasingly focused on containing global warming and subduing household greenhouse gas emissions, has taken on increasing relevance
• Within the U.S., households account for 20% of total carbon emissions – with U.S. household emissions alone surpassing those of Germany as a whole
• GeoSolar Technologies’ revolutionary SmartGreen(TM) Home system has been designed to power homes through a mix of renewable energy sources – effectively reducing the average home’s carbon footprint to near zero

When the upcoming United Nation’s Climate Change Conference, better known as ‘COP27’, kicks off in Egypt’s Sharm El-Sheikh on November 6th, it will do so amidst some of the most perilous environmental conditions the world has ever witnessed. Faced with a growing energy crisis, record greenhouse gas concentrations, and increasing extreme weather events, politicians will be at pains to deliver action on an array of issues critical to tackling the ongoing climate emergency. Ranging from urgently reducing greenhouse gas emissions, through to building resilience and adapting to the inevitable impacts of climate change, all whilst delivering on commitments to finance climate action in developing countries, conference attendees will be asked to commit to a wide array of initiatives to halt global warming on its tracks. With 40 percent of greenhouse gas (“GHG”) emissions originating from real estate, measures to decarbonize households will form an increasing priority within the global political agenda – with tackling US household emissions foremost on that list (https://ibn.fm/8bSbt). A comprehensive study encompassing 93 million individual households within the United States found that residential energy usage accounts for as much as 20 percent of GHG emissions in the United States (https://ibn.fm/A7ydM). Putting that figure into perspective – if the U.S. housing sector’s emissions were to be considered as a country, that country would represent the world’s sixth largest GHG emitter, comparable to the entirety of Brazil’s emissions and ranking significantly higher than those of Germany. Perhaps more ominously, by 2025 the United States will add an estimated 70-129 million residents and 62-105 million new homes, growing the urgent need to reduce emissions across the US housing sector. Consequently, and despite U.S. homes becoming increasingly energy efficient in recent years, U.S. household energy use and consequently, the sector’s GHG emissions, have failed to reduce as a by-product of demographic trends, necessitating the employment of additional measures to arrest the incessant growth in carbon dioxide emissions. GeoSolar Technologies (“GST”), a Colorado-based climate technology company, has sought to cater to this increasingly urgent requirement. Through the introduction of its proprietary SmartGreen(TM) Home system – an environmentally friendly, renewable energy focused technology designed to harness energy from the earth and sun to power and purify homes and automobiles without the use of fossil fuels, GeoSolar are focused to tackle the astounding thirty percent of global greenhouse gases generated by households every year. Moreover, and during a time of increasingly elevated electricity costs, the company has illustrated how the average GeoSolar-powered home could result in a negligible carbon footprint, with homeowners disbursing less than $100 per annum in utility bills (https://ibn.fm/QBDD9). Solar, wind, and hydroelectric power have long been renowned as popular and well accepted renewable energy sources, with a number of these achieving grid cost parity relative to more conventional energy sources in different jurisdictions. Whilst GeoSolar have made use of a variety of conventional forms of renewable energy within its home energy systems, it has also looked towards adopting a more holistic approach by harnessing other, more unconventional energy sources, including the likes of geothermal energy; effectively, tapping into heat generated from the Earth’s core to generate electricity (https://ibn.fm/jRt9R). The geothermal energy is than used to power heat pumps, with the latter employed to warm houses rather than having households rely on more conventional air-conditioning and gas furnace systems. With the world’s climate increasingly seen to be teetering on a precipice, global coordinated action will be essential in terms of preserving the environment as we see it today. Given the important role controlling household emission levels will play within this initiative, GeoSolar Technologies’ revolutionary SmartGreen(TM) Home system as well as its innovative use of renewable energy sources could not have come at a better time. For more information, visit the company’s website at www.GeoSolarPlus.com. NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• The United States is still the world’s largest economy and largest importer and exporter of goods and services – with strong ties to Mexico and Canada
• Mexico has reached number one as a US trade partner, with a value of $520.12 billion during the first eight months of 2022, followed by Canada
• Freight Technologies’ cloud-based marketplace, Fr8App, is simplifying Over-The-Road (“OTR”) trade and reducing the carbon footprint in the industry by directly matching OTR shippers with qualified carriers and provides 24/7 live tracking, quick pay, and driver rating features
• The company is building strategic relationships with key customers across trade industries, expanding its customer base to provide its all-in-one solution for shippers with more reliable results and lower costs

Trade is vital to America’s prosperity as the world’s largest economy and largest importer and exporter of goods and services. Trade fuels economic growth, supports good jobs, raises living standards, and helps provide families with affordable goods and services. For the first time since January of this year, Mexico overtook Canada as the number one trade partner of the United States in August, increasing trade to $520.12 billion through the first eight months of the year, according to Census Bureau data analyzed by World City (https://ibn.fm/2YU7w). The most popular point for commercial truck crossings between the United States and Mexico is Laredo, Texas, which saw an increase of 12.8%, equivalent to 246,019 vehicles during August – ranking the port number two among the 450 ports, seaports, and border crossings between the United States and Mexico. The increase has brought the total number of truck crossings in Laredo to 2.7 million, an increase of 8.9% year to date. Some of the biggest challenges experienced by freight carriers since the COVID-19 pandemic include global supply chain disruptions, increased ocean freight rates, and logistics challenges – but demand for importing and exporting is as strong as ever. Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process and provides a platform for B2B cross-border shipping across the USMCA region. The company’s mission is to revolutionize cross-border shipping by providing carriers with increased growth opportunities and shippers with flexibility, visibility, and simplicity for the once-complex process of international OTR shipping. Fr8Tech is leveraging its technology to help improve their customers’ operational efficiency and security while reducing its carbon footprint by optimizing empty miles and reducing paper consumption. Fr8App is a cloud-based marketplace that combines all aspects of a centralized control center into one platform – directly matching cross-border shippers throughout Mexico, Canada, and the United States with available carriers and drivers for their loads and capable of tracking status from start to finish. Powered by artificial intelligence and machine learning, Fr8App is the company’s B2B marketplace offering a real-time portal to connect shippers with qualified carriers. The Fr8App comes with 24/7 live tracking, quick pay, and driver ratings to make the process faster, more secure, and at the best pricing possible. The commercial trucking market is full of inefficiencies that create problems for both shippers and carriers equally, including a lack of transparency in pricing, inefficient matching, low technological penetration, and complexity of cross-border trades – Fr8App automates the process, making it more efficient and reducing logistic costs while improving security. The company is building strategic relationships with key players in the transportation industry, allowing faster growth of its customer base with enterprise accounts. With major imports and exports stemming from technology and other goods and services, the integration of these companies is allowing for Fr8Tech to provide an all-in-one solution for the inefficiencies these customers face in the transportation industry today by connecting the US, Mexico, and Canadian Marketplace (“USMCA”) with a single shipping solution. For more information, visit the company’s website at www.Fr8Technologies.com. NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT Corporate Communications IBN (InvestorBrandNetwork) Los Angeles, California www.InvestorBrandNetwork.com 310.299.1717 Office Editor@InvestorBrandNetwork.com

• Odyssey Health is a medical company specializing in the development of unique, life-saving medical products that provide solutions to unmet clinical needs, one of which is concussion, which currently does not have an FDA-approved drug
• The company has developed the PRV-002 drug candidate, which is designed to be administered intranasally where pre-clinical results have shown to be effective in treating a concussion within 30 minutes of administration
• Through its drug candidate, Odyssey hopes to reduce the risks and potential for long-term consequences associated with concussions

Up until Olympic gold medalist Katie Weatherston was forced into retirement following a series of mild traumatic brain injuries (“mTBIs”) or concussions, she and her professional career were blossoming. As a member of the Canadian national team, Katie won a gold medal in the ice hockey tournament at the 2006 Olympic Games in Turin, Italy. In 2007, she again was a gold medalist at the 2007 IIHF Ice Hockey Women’s World Championship held in Canada; a year later, at the IIHF Championship tournament held in China, she would go on to win a silver medal (https://ibn.fm/LVU6f). Indeed, Weatherston’s career comprised moments most athletes only dream of; but during an interview published in 2013 on CTV Ottawa Morning Live’s YouTube channel (https://ibn.fm/6AVQg), she asked whether it was worth the life-long consequences she could have, to which she ruefully answered, “Probably not.” The figurative beginning of the end, at least career-wise, started in 2005 when she flew over the handlebars during a bike race with her team. Then in 2006, she was hit from the back and went head first into the boards at a training camp; the team doctor cleared her after assessing her for a concussion, allowing her to get back into the game. But she suffered two more blows to the head. Within the next few days, Katie developed concussion symptoms and was eventually confirmed to have sustained a concussion, forcing her out of the game for several months. Fortunately, she eventually got back to doing what she loved, albeit for a short period, until a minor fall gave her whiplash in 2008 (https://ibn.fm/MQnOm). For the 16 years since the 2006 series of injuries, Katie told CBC in an interview, she has struggled with daily headaches, chronic exhaustion, and the sensation of her ears popping. And to cope, she has had to seek medical care in the form of, among others, physiotherapy and chiropractor appointments, which require her to fork out CA$30,000 to CA$40,000 a year. Katie had been left with prolonged or persistent post-concussion syndrome (“PPCS”) (https://ibn.fm/Caq8o). Although concussion holds the potential to upend life, causing lingering symptoms that complicate everyday activities, it currently does not have an FDA-approved treatment. This is despite the fact that between 1.6-3.8 million concussions occur in the United States every year (https://ibn.fm/N0HT1), with 10-20% of these cases likely to lead to PPCS (https://ibn.fm/cSgTP). In recognizing this gap, Odyssey Health (OTC: ODYY), a medical company developing unique, life-saving medical products that provide solutions to unmet clinical needs, embarked on the development and evaluation of PRV-002, a novel compound for the treatment of concussion. Through in-vivo animal testing, PRV-002 has been shown to have anti-inflammatory, antioxidant, and antiedematous properties that ensure it eliminates the immediate consequences of a concussion, namely swelling, oxidative stress, and inflammation in the brain while restoring proper blood flow. Additionally, animal models of concussion have demonstrated that PRV-002 reduces behavioral pathology linked to mTBI symptoms such as motor/sensory performance, anxiety, and memory impairment. Odyssey recently completed its registered Phase I trial, which was segmented into Single Ascending Dosing (“SAD”) and Multiple Ascending Dosing (“MAD”) portions, both of which evidenced that PRV-002 is safe and well-tolerated when administered to healthy subjects (https://ibn.fm/qFt73). Next, the company is planning a Phase II trial that will evaluate the efficacy of the drug candidate in concussed patients. The study will initially be domiciled in select military sites where personnel are prone to sustaining concussions during training. Designed to be delivered via the Odyssey’s novel intranasal drug delivery device, the drug candidate is meant to be administered within minutes of a concussion episode, allowing it to reverse the effects of the blow or jolt to the head. This immediate action is attributable to the intranasal delivery, which deposits the dry powder to the upper chamber of the nasal cavity for onward travel to the brain via the cranial nerve, and the drug’s lipophilic properties that enable it to cross the blood-brain barrier. Once approved, PRV-002 is poised to potentially reduce the risks posed by concussions, which have impacted the lives of many professional athletes, some of whom, like Katie Weatherston, have been forced into retirement and still have lingering symptoms such as balance problems, difficulty focusing their gaze, dizziness, depression, and chronic exhaustion (https://ibn.fm/aRX4f). For more information, visit the company’s website at www.OdysseyHealthInc.com. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

• Flora Growth signed a definitive agreement with FGH to acquire 100% of all issued and outstanding shares by way of a statutory plan of agreement
• The deal is expected to close in December following the presentation of the agreement to shareholders; the acquisition will open Flora to the German and EU medical markets, increasing the company’s international revenue and providing essential distribution to German pharmacies and a growing wholesale market
• FGH’s acquisition adds to Flora’s expanding list of subsidiaries which currently comprise Vessel Brand Inc. and JustCBD, among others, and it is expected to deliver at least $3 million in annualized cost synergies within the first year
• Luis Merchan, Flora’s Chairman and CEO, has noted that he believes the company has a path to profitability that few global cannabis companies can achieve, and the acquisition shows Flora’s commitment to achieving this profitability
• The acquisition also highlights the company’s understanding of the global cannabis space, the opportunities therein, and what it would take for it to become the undisputed market leader

Flora Growth (NASDAQ: FLGC), an internationally focused cannabis builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives, is looking to grow its product portfolio and expand its market reach with the proposed acquisition of Franchise Global Health Inc. (“FGH”), a multi-national operator in the medical cannabis and pharmaceutical industry (https://ibn.fm/Vz1cd). With principal operations in Germany, FGH’s acquisition will open Flora up to the German and European Union (“EU”) medical markets, which its management notes will significantly increase the company’s commercial international revenue. Flora signed a definitive agreement with FGH to acquire 100% of all issued and outstanding shares by way of a statutory plan of arrangement. The company expects to close the deal in December following the presentation of the agreement to shareholders. Completion of the agreement will be subject to certain closing conditions customary for transactions of this nature, including, but not limited to, approval by the Supreme Court of British Columbia. FGH will add to Flora’s expanding list of subsidiaries comprising Vessel Brand Inc. and JustCBD, among others. It is also expected to deliver at least $3 million in annualized cost synergies within the first year, mainly in reduced corporate administrative expenses. “Through this proposed acquisition, we are connecting our commercial infrastructure and medical cannabis product portfolio to the German and EU medical markets while gaining direct access to European pharmaceutical distributions,” noted Luis Merchan, Flora’s Growth’s Chairman and CEO. “We believe Franchise will significantly increase our commercial international revenue and provide essential distribution to German pharmacies and a growing wholesale market,” he added. In August, Flora released its financial results for the first half of the 2022 financial year (“H1 2022”). Most notably, the company delivered on its promise to double revenue compared to H2 2021, lauding the integration of both Vessel and JustCBD. In addition, the company’s management expressed its confidence in maintaining the current trajectory to deliver its full-year guidance due to continued growth in its House of Brands. “We continue to prudently manage our overhead and working capital as we expect to improve profitability going forward,” noted Mr. Merchan. “We believe we have a path to profitability that few global cannabis companies can achieve in this difficult moment. The execution of our key initiatives is a testament to our team’s ability to deliver on plan. We will continue to execute as we focus on profitability and long-term value creation,” he added (https://ibn.fm/3LNn5). FGH’s acquisition is poised to bolster Flora’s profitability while strengthening its market presence. The move is also a testament to the company’s commitment to its vision of global market dominance. In addition, it reflects its management’s competence and understanding of what is required for the company to grow and achieve its short-term and long-term goals. Still, most importantly, it shows Fora’s understanding of the global cannabis space, the opportunities therein, and what it would take to become the undisputed market leader. For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• The California Department of Cannabis Control (“DCC”) has reserved $20 million in funding for research prioritizing cannabis projects, including potency, health impact, medicinal use, legacy cannabis genetics, and industry health
• The medicinal and recreational cannabis market size in the US is anticipated to reach $33 billion in 2022, with a revenue outlook of $52.6 billion by 2026
• REZYFi Inc., through two wholly-owned subsidiaries, is positioned to be the first cannabis mortgage banker in the United States

The state of California Department of Cannabis Control has reserved $20 million in funding for research that prioritizes numerous cannabis topics, including potency, health impacts, medicinal use, legacy cannabis genetics, and the industry’s health. The DCC requires that research funded under the program be available publicly at no cost. The grant proposals will be accepted from November 1 through November 30, with winning research projects awarded in February 2023. The DCC research grants are making it possible for expansion in the cannabis industry through individualized research on topics that make an impact (https://ibn.fm/eWbjB). The medical and recreational cannabis market size in the United States is anticipated to reach $33 billion by the end of 2022, driven by the increase in the adult-use market. Retail sales are expected to reach $52.6 billion by 2026, according to the 2022 MJBiz Factbook (https://ibn.fm/TYDYL). The increase in the market can be attributed to consumer awareness and the legalization growing in states across the country – with four more states adding it to ballots for voters in November. There is an unmet need for cannabis companies looking for traditional banking opportunities. However, one company, REZYFi, is uniquely positioned as the first cannabis mortgage banker in the United States. REZYFi is a growth mortgage origination and specialized financing company servicing the needs of both traditional and non-traditional consumers and businesses – targeting licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing and project-specific financings, such as solar installations and real estate development projects. REZYFi operates through two wholly-owned subsidiaries – REZYFi Lending and ResMac, Inc. REZYFi Lending leverages a wide network to offer options such as 15- to 30-year fixed-rate loans, FHA loans, VA loans, reverse mortgages, jumbo loans, and adjustable-rate mortgages. The company expects increased funding in marketing and loan agents to drive significant origination growth over the next two years, further supported by the company’s launch of a high-margin cannabis division. ResMac has been in operation for 13 years, having closed more than 20,000 loans for more than 15,000 clients. Through ResMac, REZYFi operates as a direct lender and originator of residential mortgages, with active mortgage correspondent and mortgage operations. Through its correspondent segment, ResMac primarily purchases and aggregates residential mortgages from trusted third-party originators. The company is leveraging its corporate strengths to enhance the current unmet needs of the market. REZYFi is using its experience, network of independent brokers, and proprietary technology to further advance its presence as one of the first cannabis mortgage bankers working on expanding licensing into all states. Through its unique offering, REZYFi is leading the industry with a diversified approach to the real estate lending sector, positioning itself to capitalize on growth in multiple verticals in years to come. For more information, visit the company’s website at www.REZYFi.com. NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://ibn.fm/REZY